Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy
Meng-Ru Zhang,Lin-Lin Fang,Yang Guo,Qin Wang,You-Jie Li,Hong-Fang Sun,Shu-Yang Xie,Yan Liang
DOI: https://doi.org/10.2147/ijn.s454004
IF: 7.033
2024-04-09
International Journal of Nanomedicine
Abstract:Meng-Ru Zhang, 1, 2, &ast Lin-Lin Fang, 3, &ast Yang Guo, 1 Qin Wang, 1 You-Jie Li, 1 Hong-Fang Sun, 1 Shu-Yang Xie, 1 Yan Liang 1 1 Department of Biochemistry and Molecular Biology, School of Basic Medicine, Binzhou Medical University, YanTai, ShanDong, 264003, People's Republic of China; 2 Department of Clinical Medicine, Binzhou Medical University, YanTai, ShanDong, 264003, People's Republic of China; 3 RemeGen Co., Ltd, YanTai, ShanDong, 264000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Liang; Shu-Yang Xie, Department of Biochemistry and Molecular Biology, School of Basic Medicine, Binzhou Medical University, YanTai, ShanDong, 264003, People's Republic of China, Tel/Fax +86 535 6913335 ; +86 535 6913166, Email ; Cancer immunotherapy has emerged as a novel therapeutic approach against tumors, with immune checkpoint inhibitors (ICIs) making significant clinical practice. The traditional ICIs, PD-1 and PD-L1, augment the cytotoxic function of T cells through the inhibition of tumor immune evasion pathways, ultimately leading to the initiation of an antitumor immune response. However, the clinical implementation of ICIs encounters obstacles stemming from the existence of an immunosuppressive tumor microenvironment and inadequate infiltration of CD8 + T cells. Considerable attention has been directed towards advancing immunogenic cell death (ICD) as a potential solution to counteract tumor cell infiltration and the immunosuppressive tumor microenvironment. This approach holds promise in transforming "cold" tumors into "hot" tumors that exhibit responsiveness to antitumor. By combining ICD with ICIs, a synergistic immune response against tumors can be achieved. However, the combination of ICD inducers and PD-1/PD-L1 inhibitors is hindered by issues such as poor targeting and uncontrolled drug release. An advantageous solution presented by stimulus-responsive nanocarrier is integrating the physicochemical properties of ICD inducers and PD-1/PD-L1 inhibitors, facilitating precise delivery to specific tissues for optimal combination therapy. Moreover, these nanocarriers leverage the distinct features of the tumor microenvironment to accomplish controlled drug release and regulate the kinetics of drug delivery. This article aims to investigate the advancement of stimulus-responsive co-delivery nanocarriers utilizing ICD and PD-1/PD-L1 inhibitors. Special focus is dedicated to exploring the advantages and recent advancements of this system in enabling the combination of ICIs and ICD inducers. The molecular mechanisms of ICD and ICIs are concisely summarized. In conclusion, we examine the potential research prospects and challenges that could greatly enhance immunotherapeutic approaches for cancer treatment. Keywords: antitumor therapy, immunogenic cell death, co-delivery, immune-checkpoint inhibitors, stimulus-responsive nanocarriers Cancer, being a substantial global public-health concern, is projected to 28.4 million cases worldwide by the year 2040. 1 In recent decades, cancer immunotherapy has made noteworthy strides. In recent decades, cancer immunotherapy has made significant progress. Currently, it predominantly focuses on two domains. The first is the activation of key components within the immune system, including cancer vaccines, 2 cytokine therapy, 3 and adoptive T-cell therapy. 4 The second domain involves the suppression of immune-checkpoint molecules, such as immune-checkpoint blocking (ICB). 5,6 Immune-checkpoint molecules refer to the small proteins produced by immune cells in the body that regulate effector function. Tumor cells evade and survive the body's immune system by overactivating immune-checkpoint molecules. Immune-checkpoint inhibitors (ICIs) can prevent the overactivation of immune checkpoint inhibitors, allowing immune cells to eliminate cancer cells. ICIs exert their antitumor effects mainly through PD-1/PD-L1 inhibitors. 7 PD-1/PD-L1 inhibitors include PD-1 antibodies and PD-L1 antibodies, which can bind to PD-1 and PD-L1 respectively, preventing the binding of cancer cells and T cells. Then promoting the T cell-mediated killing and clearance of tumors. However, numerous tumors exhibit a poor response to the use of PD-1/PD-L1 checkpoint inhibitors alone. 8–10 This is due to the fact that the tumors are mostly "cold" tumors, which are manifested as a low immunogenicity of the tumor cells. Furthermore, the immunosuppressive tumor microenvironment (ITM) significantly impedes the infiltration and function of cytotoxic lymphocytes (CTLs), which contributes to sustained tumor growth. Resear -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology